Anush Lingamoorthy

Anush Lingamoorthy

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 December 2022 in Proceedings of the ACM on Interactive, Mobile, Wearable and Ubiquitous Technologies
Verified
Journal Article
Open access
AWAmanda Watson
Amanda Watson
CKClaire Kendell
Claire Kendell
ALAnush Lingamoorthy
Anush Lingamoorthy
ILInsup Lee
Insup Lee
JWJames Weimer
James Weimer
Spectroscopy, the study of the interaction between electromagnetic radiation and matter, is a vital technique in many disciplines. This technique is limited to lab settings, and, as such, sensing is isolated and infrequent. Thus, it can only provide a brief snapshot of the monitored parameter. Wearable technology brings sensing and tracking technologies out into everyday life, creating longitudinal datasets that provide more insight into the monitored parameter. In this paper, we describe Lumos, an open-source device for wearable spectroscopy research. Lumos can facilitate on-body spectroscopy research in health monitoring, athletics, rehabilitation, and more. We developed an algorithm to determine the spectral response of a medium with a mean absolute error of 13nm. From this, researchers can determine the optimal spectrum and create customized sensors for their target application. We show the utility of Lumos in a pilot study, sensing of prediabetes, where we determine the relevant spectrum for glucose and create and evaluate a targeted tracking device.

6 March 2025 in Journal of Medical Internet Research
Verified
Journal Article
Open access
ARAlexis M. Roth
Alexis M. Roth
ADAlly D'ANgelo
Ally D'ANgelo
DGDavid Gordon
David Gordon
BCBenjamin Cocchiaro
Benjamin Cocchiaro
ALAnush Lingamoorthy
Anush Lingamoorthy
CBCameron Baston
Cameron Baston
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: For over a decade, drug overdose has been the leading cause of injury and accidental death in the United States. Most fatal overdoses involve opioids and occur during solitary drug use events when no one is available to initiate lifesaving responses (e.g., naloxone).​ While there is a growing interest in devices providing early overdose detection and automated response, little research has engaged end users in a device design process.​ Objective: To describe user experience, perceived harms and benefits, and the acceptability of a shoulder-mounted wearable sensor among people who inject drugs who wore a device prototype for seven days, and to explore real-time responses that could be incorporated into a next generation sensor. Methods: Individuals ≥18 years reporting past week injection drug use were recruited from a walk-in substance use disorder clinic in Camden, NJ, USA. Participants completed a brief survey assessing socio-demographics and recent drug use and were assigned a sensor prototype that they were asked to wear near-continuously for seven days. At endline, they completed semi-structured interviews exploring acceptability, usability, and form and function preferences for next-generation devices with integrated automated response options. Structured field notes and transcripts were analyzed to identify key themes and design considerations. Results: Participants (n=23) had a median age of 41 years. Most were primarily non-Hispanic White (65%) males (61%), experiencing homelessness (57%) who reported daily injection drug use (74%) within 3-months and receipt of opioid use disorder medication within a month (74%). Sixteen completed an exit interview. They found the concept of a shoulder-mounted overdose detection device acceptable and unanimously endorsed the need for long-lasting discreet devices. They emphasized the importance of having multiple response options that wearers could tailor to their individual circumstances and preferences, noting some might prefer an automatic call to emergency services, while others might prefer to alert a peer. Participants expressed a preference for solutions that alert first responders over automated biomedical solutions, such as naloxone injection, because of concerns about device error (e.g., false positives) leading to precipitated withdrawal. Conclusions: After wearing a shoulder-mounted protype, this small group of participants found the idea acceptable and provided feedback to improve usability and design. Data suggest that a variety of devices with differing functions, size, and capacity will be needed to meet user needs and increase the likelihood of adoption once devices come to market.

21 June 2023
Verified
Conference Paper
Open access
ALAnush Lingamoorthy
Anush Lingamoorthy
AWAmanda Watson
Amanda Watson
DGDavid Gordon
David Gordon
AMAyan Mandal
Ayan Mandal
KHKorey Henderson
Korey Henderson
NKNagarajan Kandasamy
Nagarajan Kandasamy
Naloxone is a life-saving drug capable of reversing a fatal opioid overdose. Although this drug has existed for over 50 years, opioid overdose-related deaths have consistently risen and surpassed 120,000 globally in 2021. Opioids induce respiratory depression by activating μ-opioid receptors at specific sites in the central nervous system. This results in overdose deaths caused by slow and shallow breathing, also known as opioid-induced respiratory depression. 1.6 million individuals suffer from opioid use disorder annually, making them at high risk of overdose, primarily due to the increasing prevalence of Fentanyl. Over 52% of these deaths occur when the individual is alone. Immediate response to an overdose by delivering naloxone can save the individual's life. To solve this problem, we developed a closed-loop sensor-driven auto-injector that can determine a fatal overdose and inject naloxone. 76% of this population is willing to wear such a device on the shoulder, a canonical injection site. This paper presents the DOVE, a shoulder-based opioid overdose detection and reversal device. It noninvasively measures the subject's motion state and changes in blood oxygen levels (SpO2) along with the respiration state. These biomarkers are measured from the shoulder using an optical sensor and accelerometer to determine if a fatal overdose occurred. We evaluated our DOVE device against an FDA-cleared commercial pulse oximeter by inducing apneic events as they have very similar SpO2 trends to an overdose. Results show that SpO2 can be measured on the shoulder across different skin tones with an accuracy of 96.8% and a high Pearson correlation of 0.766 (p < 0.0001).

15 February 2026 in Sensors
Verified
Journal Article
Open access
PDF file
KKKatie N. Kanter
Katie N. Kanter
AWAaron Wang
Aaron Wang
DGDavid Gordon
David Gordon
ASAdina Singer
Adina Singer
JBJacob S. Brenner
Jacob S. Brenner
CBCameron Baston
Cameron Baston
The shoulder may be an effective central site for continuous oxygen saturation (SpO2) monitoring but studies of shoulder-mounted pulse oximetry technology are limited. We hypothesized that an alternative location would be similar in function and user acceptance to a standard FDA-cleared finger-based pulse oximeter. We conducted a quantitative and descriptive pilot study of two prototype biosensor designs in patients with clinical suspicion of hypoxic episodes at an outpatient sleep center. Participants wore two prototype biosensors—the primary a shoulder-mounted adhesive and the secondary a combination ring–bracelet—in addition to a control FDA-approved finger-based pulse oximeter. We assessed the comfort of the devices based on a survey. We monitored 27 patients during an overnight polysomnography study. Participants rated the shoulder-mounted device more highly than the control device on a Likert scale survey of comfort (4.6 out of 5 versus 3.1 out of 5). Open-ended questionnaires showed that the two major criticisms of the control and ring devices were devices falling off and disruption to sleep, while only one participant commented on the shoulder device specifically. We also investigated SpO2 agreement between the primary shoulder-mounted prototype and the control finger-based pulse oximeter. This study confirms that alternative configurations for SpO2 monitoring offer potential as well-tolerated devices with preliminary findings of acceptable agreement. Problems with traditional pulse oximetry, such as false readings of hypoxia due to device removal or noisy data, were encountered less frequently in shoulder-mounted pulse oximetry than in the commercial finger-based device. Future directions include studies of additional populations that are at risk of respiratory collapse and surveys to elicit specific feedback on the configurations, whether positive or negative.

19 December 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
KKKatie Kanter
Katie Kanter
AWAaron Wang
Aaron Wang
DGDavid Gordon
David Gordon
ASAdina Singer
Adina Singer
JBJacob S Brenner
Jacob S Brenner
CBCameron Baston
Cameron Baston
The shoulder may be an effective central site for continuous oxygen saturation (SpO2) monitoring but studies of shoulder-mounted pulse oximetry technology are limited. We hypothesized that a shoulder-based biosensor device would be similar in function and user acceptance to a standard FDA-cleared finger-based pulse oximeter. We conducted a quantitative and descriptive pilot study of two prototype biosensor designs in patients with clinical suspicion of hypoxic episodes at an outpatient sleep center. Participants wore two prototype biosensors–the first a shoulder-mounted adhesive and the second a combination ring-bracelet–in addition to a control FDA-approved finger-based pulse oximeter. We assessed SpO2 agreement among the devices as well as the comfort of the devices based on a survey. We monitored 27 patients during an overnight polysomnography study. The prototype shoulder pulse oximeter SpO2 readings agreed with the control values of the commercial finger-based pulse oximeter with a 0.72% mean absolute error. Participants rated the shoulder-mounted device more highly than the control device on a Likert-scale survey of comfort (4.6 out of 5 versus 3.1 out of 5). Open-ended questionnaires showed that the two major criticisms of the control and ring devices were devices falling off and disruption to sleep while only one participant commented on the shoulder device, specifically. This study confirms that alternative configurations for SpO2 monitoring offer potential as accurate and well-tolerated devices. Problems with traditional pulse oximetry, such as false readings of hypoxia due to device removal or noisy data, were encountered less frequently in shoulder-mounted pulse oximetry than in the commercial finger-based device. Future directions include studies of additional populations that are at risk of respiratory collapse and surveys to elicit specific feedback on the configurations, whether positive or negative.

18 June 2025
Verified
Thesis
Closed access
ALAnush Lingamoorthy
Anush Lingamoorthy
NKNagarajan Kandasamy
Nagarajan Kandasamy
JBJacob S. Brenner
Jacob S. Brenner
Wearable health monitoring devices have gained increasing attention due to their potential to provide continuous, real-time data for managing chronic and acute medical conditions. However, existing systems often lack usability, reliability, or accessibility, especially among high-risk populations such as people who use opioids (PWUOs) or individuals living with diabetes. This dissertation addresses these challenges by developing and evaluating two distinct wearable systems that leverage optical spectroscopy for non-invasive monitoring, targeting opioid overdose detection and capillary blood glucose estimation, respectively. While both systems utilize optical principles, they are designed as separate research pillars with unique sensor configurations, algorithmic frameworks, and deployment contexts. The first pillar centers on opioid overdose detection through the DOVE system (Detection of Opioid-related Ventilatory Emergency), a shoulder-mounted, autonomous device designed for PWUOs. Opioid overdose remains a critical public health crisis, with over 120,000 overdose deaths per year, and a significant portion of fatalities occurring when individuals use opioids alone, lacking timely intervention. DOVE addresses this need by integrating multimodal sensors, including photoplethysmography (PPG) for oxygen saturation (SpO₂) measurement, accelerometry for motion detection, and respiration rate estimation. The system's architecture optimizes the challenges of shoulder-based sensing, including low perfusion and high motion artifacts. An adaptive LED intensity normalization technique accommodates diverse skin tones, while a ternary spiking neural network (SNN) enables low-power, hypoxia classification. In feasibility studies, DOVE demonstrated reliable SpO₂ estimation with a mean absolute error (MAE) of 4.91% during controlled hypoxia events, maintaining performance under varying environmental conditions. The system's utility was further evaluated in a real-world field study involving 12 PWUOs over five days, where an attention-based BiLSTM model accurately distinguished opioid use from daily activity with over 91% accuracy. These results validate the feasibility of non-invasive, autonomous overdose detection in real-world settings. The second research pillar focuses on non-invasive glucose monitoring through the GlucoLux system. Diabetes management often requires continuous glucose monitoring (CGM), yet current systems are invasive, expensive, and inaccessible to many, particularly in low-resource settings. GlucoLux leverages optical spectroscopy, utilizing a multi-wavelength LED-photodiode configuration to detect glucose fluctuations non-invasively from the fingertip. The sensor array spans visible and near-infrared (NIR) wavelengths, capturing subtle changes in light absorption corresponding to capillary glucose levels. The system's ensemble learning model, trained on data from a seven-participant study, achieved a mean absolute relative difference (MARD) of 5.4%, with 99.97% of estimates falling within Clarke Grid zones A and B. Cross-validation against commercial CGMs demonstrated consistent accuracy, even across diverse skin tones, highlighting the potential for non-invasive glucose tracking. This dissertation contributes to the field of wearable health monitoring by advancing optical biosensing methods specifically tailored for high-impact, underserved healthcare needs. By co-designing hardware and algorithms with end-user involvement and clinical validation, we bridge a crucial gap between laboratory innovation and real-world application.